Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes

Diabetes Care

Volumn 37, Issue 8, 2014, Pages 2253-2260

  Goldberg, Ronald B ^a   Temprosa, Marinella G ^b   Mather, Kieren J ^c   Orchard, Trevor J ^d   Kitabchi, Abbas E ^e   Watson, Karol E ^f  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; GLUCOSE; INSULIN; METFORMIN; PLACEBO; TISSUE PLASMINOGEN ACTIVATOR; ANTIDIABETIC AGENT;

ADULT; ANTHROPOMETRY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; FIBRINOGEN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; LOW CALORY DIET; LOW FAT DIET; MAJOR CLINICAL STUDY; ORAL GLUCOSE TOLERANCE TEST; PHYSICAL ACTIVITY; PREVENTIVE MEDICINE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; WEIGHT CHANGE; AGED; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FEMALE; GLUCOSE TOLERANCE TEST; LIFESTYLE; MALE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BODY WEIGHT; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LIFE STYLE; MALE; METFORMIN; MIDDLE AGED; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84904989260     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-2471     Document Type: Article

References (17)

1. Knowler WC, Barrett-Connor E, Fowler S.E., et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403
2. Kitabchi AE, Temprosa M, Knowler W.C., et al.; Diabetes Prevention Program Research Group. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes 2005; 54: 2404-2414
3. Festa A, D'Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-47
4. Haffner SM. Insulin resistance, inflammation, and the prediabetic state. Am J Cardiol 2003; 92(Suppl. 1): 18J-26J
5. Hämäläinen H, Rönnemaa T, Virtanen A, et al.; Finnish Diabetes Prevention Study Group. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. Diabetologia 2005; 48: 2248-2253
6. Haffner S, Temprosa M, Crandall J., et al.; Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 2005; 54: 1566-1572
7. Diabetes Prevention Program Research Group. Lipid, lipoproteins, C-reactive protein, and hemostatic factors at baseline in the diabetes prevention program. Diabetes Care 2005; 28: 2472-2479
8. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-1197
9. Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care 2003; 26: 977-980
10. Putz DM, Goldner WS, Bar R.S., Haynes WG, Sivitz WI. Adiponectin and C-reactive protein in obesity, type 2 diabetes, and monodrug therapy. Metabolism 2004; 53: 1454-1461
11. Lowe GD, Danesh J, Lewington S., et al. Tissue plasminogen activator antigen and coronary heart disease. Prospective study and meta-analysis. Eur Heart J 2004; 25: 252-259
12. Hamman RF, Wing RR, Edelstein S.L., et al.; Diabetes Prevention Program Research Group. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 2006; 29: 2102-2107
13. Du XL, Edelstein D, Rossetti L., et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci U S A 2000; 97: 12222-12226
14. Lachin JM, Christophi CA, Edelstein S.L., et al.; DDK Research Group. Factors associated with diabetes onset during metformin versus placebo therapy in the diabetes prevention program. Diabetes 2007; 56: 1153-1159
15. He G, Pedersen SB, Bruun J.M., Lihn AS, Richelsen B. Metformin, but not thiazolidinediones, inhibits plasminogen activator inhibitor-1 production in human adipose tissue in vitro. Horm Metab Res 2003; 35: 18-23
16. Bergheim I, Guo L, Davis M.A., et al. Metformin prevents alcohol-induced liver injury in the mouse: Critical role of plasminogen activator inhibitor-1. Gastroenterology 2006; 130: 2099-2112
17. Goldberg RB, Temprosa M, Haffner S., et al.; Diabetes Prevention Program Research Group. Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group. Diabetes Care 2009; 32: 726-732